Orgenesis Inc. (ORGS): Price and Financial Metrics
GET POWR RATINGS... FREE!
ORGS Stock Summary
- ORGENESIS INC's market capitalization of $49,558,765 is ahead of merely 13.66% of US-listed equities.
- With a year-over-year growth in debt of -51.72%, ORGENESIS INC's debt growth rate surpasses just 5.2% of about US stocks.
- In terms of twelve month growth in earnings before interest and taxes, ORGENESIS INC is reporting a growth rate of -108.67%; that's higher than only 13.62% of US stocks.
- Stocks that are quantitatively similar to ORGS, based on their financial statements, market capitalization, and price volatility, are SNCE, RVP, INDO, XOMA, and LEV.
- Visit ORGS's SEC page to see the company's official filings. To visit the company's web site, go to www.orgenesis.com.
ORGS Valuation Summary
- ORGS's price/sales ratio is 1.7; this is 66% lower than that of the median Healthcare stock.
- Over the past 131 months, ORGS's EV/EBIT ratio has gone up 972.7.
Below are key valuation metrics over time for ORGS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ORGS | 2022-12-02 | 1.7 | 1.7 | -8.8 | -9.2 |
| ORGS | 2022-12-01 | 1.7 | 1.7 | -8.8 | -9.1 |
| ORGS | 2022-11-30 | 1.7 | 1.7 | -8.8 | -9.2 |
| ORGS | 2022-11-29 | 1.7 | 1.7 | -8.8 | -9.2 |
| ORGS | 2022-11-28 | 1.8 | 1.8 | -9.2 | -9.6 |
| ORGS | 2022-11-25 | 1.9 | 1.9 | -9.8 | -10.1 |
ORGS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ORGS has a Quality Grade of F, ranking ahead of 4.67% of graded US stocks.
- ORGS's asset turnover comes in at 0.277 -- ranking 161st of 677 Pharmaceutical Products stocks.
- ACRX, ASMB, and JNJ are the stocks whose asset turnover ratios are most correlated with ORGS.
The table below shows ORGS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.277 | 0.850 | 4.262 |
| 2021-03-31 | 0.156 | 1.388 | 7.853 |
| 2020-12-31 | 0.070 | 1.000 | -0.286 |
| 2020-09-30 | 0.128 | 0.792 | -3.802 |
| 2020-06-30 | 0.209 | 0.571 | -3.077 |
| 2020-03-31 | 0.290 | 0.495 | -3.168 |
ORGS Price Target
For more insight on analysts targets of ORGS, see our ORGS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $9.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
ORGS Stock Price Chart Interactive Chart >
ORGS Price/Volume Stats
| Current price | $1.86 | 52-week high | $4.04 |
| Prev. close | $1.92 | 52-week low | $1.13 |
| Day low | $1.86 | Volume | 7,981 |
| Day high | $1.92 | Avg. volume | 60,070 |
| 50-day MA | $1.60 | Dividend yield | N/A |
| 200-day MA | $2.28 | Market Cap | 47.52M |
Orgenesis Inc. (ORGS) Company Bio
Orgenesis Inc., a service and research company, focus on the development and manufacture of cell therapy for advanced medicinal products in the field of regenerative medicine industry. The company was founded in 2008 and is based in Germantown, Maryland.
Latest ORGS News From Around the Web
Below are the latest news stories about ORGENESIS INC that investors may wish to consider to help them evaluate ORGS as an investment opportunity.
Orgenesis Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS LagsOrgenesis ( NASDAQ:ORGS ) Third Quarter 2022 Results Key Financial Results Revenue: US$7.99m (down 7.9% from 3Q 2021... |
Loss-Making Orgenesis Inc. (NASDAQ:ORGS) Expected To Breakeven In The Medium-TermOrgenesis Inc. ( NASDAQ:ORGS ) is possibly approaching a major achievement in its business, so we would like to shine... |
Orgenesis Achieves Revenue of $8.0 Million for the Third Quarter of 2022Secures up to $50 Million of Funding from Metalmark Capital Partners Expected to Accelerate Rollout of Point-of-Care Services Reduces operating expenses by 49% to achieve nearly breakeven income from operation for the third quarter of 2022 Orgenesis to Host Conference Call on Friday, November 11, 2022 at 8:00 AM Eastern Time GERMANTOWN, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potentia |
Orgenesis Schedules Third Quarter 2022 Business Update Conference CallGERMANTOWN, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will host a conference call at 8:00 AM Eastern Time on Friday, November 11, 2022 to discuss the company’s corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 fo |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday! |
ORGS Price Returns
| 1-mo | 46.46% |
| 3-mo | -1.59% |
| 6-mo | -21.52% |
| 1-year | -43.98% |
| 3-year | -31.62% |
| 5-year | -58.90% |
| YTD | -35.42% |
| 2021 | -36.00% |
| 2020 | -3.43% |
| 2019 | -0.43% |
| 2018 | -18.68% |
| 2017 | 54.65% |
Loading social stream, please wait...